方盛製藥(603998.SH)血塞通分散片進入2019版國家醫保目錄
格隆匯8月21日丨方盛製藥(603998.SH)宣佈,根據國家醫療保障局、人力資源社會保障部印發的《關於印發〈國家基本醫療保險、工傷保險和生育保險藥品目錄〉的通知》【醫保發〔2019〕46號】(“《2019版醫保目錄》”),公司主要產品之一血塞通分散片本次新進入《2019版醫保目錄》,公司及控股子公司其他主要產品本次無退出《2019版醫保目錄》的情況。
血塞通分散片,主要成分為五加科人蔘屬植物三七提取物,臨牀上主要用於活血祛瘀,通脈活絡,抑制血小板聚集和增加腦血流量;也可用於腦絡瘀阻,中風偏癱,心脈瘀阻,胸痺心痛;腦血管後遺症,冠心病心絞痛屬上述證候者。
公司於2004年12月取得血塞通分散片《新藥證書》(編號:國藥證字Z20040127)。
血塞通分散片為公司主要產品之一,2018年實現銷售收入8194.83萬元(佔公司當期營業收入的7.80%),毛利潤為4436.76萬元(佔公司當期毛利潤的5.70%);2019年1-3月實現銷售收入1821.11萬元(佔公司當期營業收入的7.63%),毛利潤為1004.86萬元(佔公司當期毛利潤的5.86%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.